普罗布考联合阿托伐他汀治疗急性脑梗死患者的疗效及安全性分析  

Effi cacy and Safety Analysis of Probucol Combined with Atorvastatin in the Treatment of Patients with Acute Cerebral Infarction

作　　者：黄圣明[1] 刘书芳[1] 王明科[1] HUANG Sheng-ming;LIU Shu-fang;WANG Ming-ke(Department of Neurology,Luohe Central Hospital,Luohe 462000,China)

机构地区：[1]漯河市中心医院神经内科,漯河462000

出　　处：《中国合理用药探索》2022年第10期41-46,共6页Chinese Journal of Rational Drug Use

基　　金：2016年度漯河市青年拔尖人才科研课题(LBJZ201601);2018年度河南省科学技术厅重点研发与推广专项(182102310229);2019年度河南省医学科技攻关计划项目(LHGJ20191412)。

摘　　要：目的:探究普罗布考联合阿托伐他汀治疗急性脑梗死(ACI)患者的临床疗效及用药安全性。方法:选择2020年1月~2021年1月本院收治的122例ACI患者为研究对象,按照随机数字表法分为对照组(n=58)和观察组(n=64)。对照组在常规治疗基础上给予阿托伐他汀,观察组在对照组治疗基础上加用普罗布考。比较两组临床疗效、血脂指标[血浆总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)]、免疫功能指标[基质金属蛋白酶9(MMP-9)、C反应蛋白(CRP)、降钙素原(PCT)]、美国国立卫生研究院卒中量表(NIHSS)评分、日常生活能力(Barthel)指数及不良反应发生率。结果:观察组临床治疗总有效率(95.31%)高于对照组(82.76%,χ2=5.037,P<0.05),且整体疗效优于对照组(Z=-2.049,P<0.05)。治疗后,两组患者的TC、TG、LDL-C、PCT、CRP、MMP-9水平均低于治疗前,且观察组上述指标均低于对照组(P<0.05)。两组治疗后的Barthel指数呈增高趋势、NIHSS评分呈下降趋势,且观察组改善幅度均大于对照组(P<0.05)。两组不良反应发生率比较无统计学差异(P>0.05)。结论:普罗布考联合阿托伐他汀疗效确切,可有效调节ACI患者的血脂水平、抑制炎症反应、改善患者神经功能,提高其日常独立活动生活能力,且不良反应少,临床安全性高。Objective:To explore the clinical eff ect and safety of probucol combined with atorvastatin in the treatment of patients with acute cerebral infarction(ACI).Methods:A total of 122 patients with ACI in our hospital from January 2020 to January 2021 were selected as the research objects.According to the random number table method,the selected patients were divided into the control group(n=58)and the observation group(n=64).The control group was given atorvastatin on the basis of conventional treatment,and the observation group was given probucol on the basis of the control group.The clinical curative eff ect and blood lipids index[plasma total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),triglyceride(TG)],immune function index[matrix metalloproteinases 9(MMP 9),C reactive protein(CRP)and procalcitonin(PCT)],the National Institutes of Health stroke scale(NIHSS)score,Barthel index and incidence of adverse reactions were compared in the two groups.Results:The total eff ective rate of observation group(95.31%)was higher than that of the control group(82.76%,χ^(2)=5.037,P<0.05);and the overall curative eff ect was better than that of the control group(Z=-2.049,P<0.05).After treatment,the levels of TC,TG,LDL-C,PCT,CRP,and MMP-9 in both groups were signifi cantly lower than those before treatment,and the above indexes in the observation group were lower than those in the control group(P<0.05).The Barthel score of the two groups showed a signifi cantly higher trend after treatment,and the NIHSS score showed a downward trend,and the improvement amplitude of the observation group was greater than that of the control group(P<0.05).There was no signifi cant diff erence in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Probucol combined with atorvastatin has defi nite effi cacy,which can eff ectively regulate the blood lipid level,inhibit infl ammatory reaction,improve the neurological function of patients and improve their daily independent activities,with less adverse reactions and

关 键 词：普罗布考 阿托伐他汀 急性脑梗死 血脂水平 炎症因子 安全性 

分 类 号：R743.3[医药卫生—神经病学与精神病学]